NextDose is a web-based Bayesian dose forecasting tool.  

11-Sep-21 Bug Fix for predicted next to last dose for cumulative AUC which was occasionally incorrect due to rounding error

16-Jul-2021 Bug fix for 'Actual Dose' display on Results page when hematocrit is used to standardize predictions.

25-May-2021 Bug fix when 'what if' calculation used with cumulative AUC target. Bug fix when end infusion time specified before dose start time.

18-Mar-2021 Posaconazole model released for NextDose. Trough target option added to prediction of FirstDose.

24-Dec-2020 Single dose infusion duration was incorrect if it followed repeated dose infusions with a different dosing interval. This has been corr ected.

12-Dec-2020 Height was not imputed unless at least one dose given. This restriction has been removed.

11-Dec-2020 TAD target may use target dosing interval for trough time (CssTroughDI) 

19-Nov-2020: Feature removal request: MIC observation type removed from gentamicin, amikacin, vancomycin.

11-Nov-2020:  Bug occurring with repeated infusions with different infusion durations has been fixed.

24-Oct-2020: Tobramycin models released for NextDose. The tobramycin models and parameters are based on those for gentamcin becuase the PK is very similar for both drugs.

22-Sep-2020: Genotype information for CYP4F2 and VKORC1 on Patient Details page expanded to specify the rs genotype identifier.

09-Sep-2020: Additional target type options with fixed AUC integration intervals. The busulfan option is for AUC over 4 days. The vancomycin option if for a steady state AUC over 48 h. These options make it simpler to use recommended AUC targets with these integration intervals.

08-Aug-2020: Dabigatran models released for NextDose. Algorithm improved for proposed dose calculation when there are both  IV and PO routes.

07-Jul-2020: Repeated dose algorithm re-written to improve occasion detection and overlapping dose implmentation. Equivalent Css average target shown when AUC target requested. Warning shown for tacrolimus if day of transplant not supplied.

01-Jun-2020: Patient Details used to specify Actual, Test or Demo type. Instances (date-time) list uses colour to distinguish Results calculated with Actual patient data or What If (simulation) data, or changed data before Results. Results format changed using colours and tables. Individual PKPD and covariate variables displayed for each occasion.

16-Apr-2020: Hydroxychloroquine whole blood concentration model added based on Carmichael 2003 population PK analysis.

11-Feb-2020: Free text entry boxes for Patient Details and Comments on the Printable Results Report have been made more flexible to allow users to record more information.

01-Jun-2019: Schwartz creatinine clearance changed to use gestational age < 40 instead of post-mentstrual age < 40 weeks.

04-Apr-2019  Sumpter method for prediction of  fat free mass fraction of adult value capped at 1 for premature boys.

11-Mar-2019: CYP3A5 genotype variants added as observation type  for tacrolimus.

03-Mar-2019: Albumin added as observation type for mycophenolate.

12-Feb-2019:  Target conc for mycophenolate changed from 40 to 50 mcg/L unbound.

28-Jan-2019: The home pages for NextDose and dev.NextDose have been simplified. Information about NextDose that was on the home pages is now accessible through this web.

27-Jan-2019: Five new medicine models have been tested using dev.NextDose (gentamicin, amikacin, vancomycin, caffeine and mycophenolate). These models are now available for use with NextDose.

29-Jul-2018: Target dose predictions are now based on covariates (fixed effects) at the end of dosing intervals rather than the start. This should give better predictions when covariates change during a dosing interval such as the empirical time varying clearance of busulfan.

29-Jul-2018: Choice between using between occasion variability (BOV) with between subject variability (BSV) or BSV alone for dose prediction. See Dose Prediction.

Copyright reserved | Developed by Sam Holford & Nick Holford 2012-2020